Higher Acuity Shift And Medicaid Dependence Will Shape Future Margin Compression

Catalysts

About Tenet Healthcare

Tenet Healthcare operates acute care hospitals and a large network of ambulatory surgery centers in the United States.

What are the underlying business or industry changes driving this perspective?

• The move toward higher acuity procedures in both hospitals and USPI ASCs raises case intensity. This can lift revenue per case but may also increase capital needs and clinical cost complexity, with mixed implications for net margins if pricing or payer mix weakens.
• Ongoing shifts in payer mix, including the 17% decline in exchange revenues and a related rise in uninsured volumes, may pressure collections and bad debt expense. This can weigh on hospital segment revenue and earnings if these trends persist.
• Greater reliance on supplemental Medicaid programs and state-directed payments increases exposure to policy and rate decisions that Tenet Healthcare does not control. This creates potential volatility in Medicaid revenue streams and adjusted EBITDA.
• Expanded reliance on technology driven cost efficiencies, including automation and AI supported processes, can support margins in the near term. Over time this may yield fewer incremental savings, which could limit further adjusted EBITDA margin improvement from current levels.
• Continued capital allocation toward USPI M&A and share repurchases, with more than US$300 million expected M&A spend and US$1.36b deployed to buybacks in the first half of 2026, may constrain balance sheet flexibility if cash flows moderate. This could affect future earnings growth and leverage metrics.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Tenet Healthcare's revenue will grow by 3.3% annually over the next 3 years.
• Analysts assume that profit margins will shrink from 10.3% today to 6.8% in 3 years time.
• Analysts expect earnings to reach $1.6 billion (and earnings per share of $23.19) by about September 2029, down from $2.2 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $1.2 billion.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 14.2x on those 2029 earnings, up from 9.5x today. This future PE is lower than the current PE for the US Healthcare industry at 24.8x.
• Analysts expect the number of shares outstanding to decline by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.66%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Exchange revenues declined 17% and exchange admissions declined 13.5% in the second quarter of 2026, with a roughly one to one shift of these patients into the uninsured category. This could pressure collections, raise bad debt expense and weigh on Tenet Healthcare's hospital revenue and net margins over time.
• Tenet Healthcare is seeing increased reliance on supplemental Medicaid programs and state-directed payments, including US$92 million of out-of-period supplemental Medicaid revenues and an expected US$140 million contribution from certain supplemental Medicaid programs in 2026. This ties a growing share of earnings and cash flow to policy decisions and program timing that may change.
• Capital deployment plans include more than US$300 million of USPI M&A spend in 2026 and US$1.36b already allocated to repurchase almost 7 million shares in the first half of 2026, with a further US$2b buyback authorization. This could reduce balance sheet flexibility if operating trends weaken and affect future earnings, free cash flow and leverage metrics.
• The business is benefiting from a wide range of cost efficiency initiatives, including traditional productivity measures, clinical operations changes and technology driven automation and AI. If these savings taper as management suggests category 1 alone is not adequate over the next few years, the scope for further adjusted EBITDA margin expansion and earnings growth could narrow.
• Tenet Healthcare is pushing steadily into higher acuity procedures in both hospitals and USPI surgery centers, including orthopedics, robotics, bariatrics, cardiovascular, more complex GI and ophthalmology. This raises revenue per case but also increases clinical complexity, capital needs and regulatory exposure, creating a risk that any misstep in execution or reimbursement pressure could affect long term revenue growth and net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $285.1 for Tenet Healthcare based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $315.0, and the most bearish reporting a price target of just $260.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $24.1 billion, earnings will come to $1.6 billion, and it would be trading on a PE ratio of 14.2x, assuming you use a discount rate of 7.7%.
• Given the current share price of $263.46, the analyst price target of $285.1 is 7.6% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.